Literature DB >> 21813307

Spinal cord compression in young children with type VI mucopolysaccharidosis.

Dafne Dain Gandelman Horovitz1, Tatiana de Sá Pacheco Carneiro Magalhães, Alessandra Pena e Costa, Luis Eduardo Carelli, Daniel Souza e Silva, Anna Patricia Freitas de Linhares e Riello, Juan Clinton Llerena.   

Abstract

Spinal cord compression (SCC) is a known complication of mucopolysaccharidosis type VI (MPS VI) secondary to atlantoaxial subluxation, craniovertebral stenosis, posterior longitudinal ligament hypertrophy, or dural thickening. SCC is expected to occur in the natural history of the disease, regardless of enzyme replacement therapy (ERT), as intravenous enzyme does not cross the blood-brain barrier. We describe six MPS VI children with SCC, all diagnosed before 7years of age. Within this group, four of the children were diagnosed with SCC after the introduction of ERT. We hypothesize that these patients may illustrate the previously undetected risk of increased joint mobility caused by ERT which may have contributed to increased cervical instability by loosening the neck joint, thus leading to or unmasking SCC. We reinforce the need for close follow-up of SCC, periodic neurological assessment, spine imaging, and neurophysiology in all MPS VI patients before and during ERT. Neurophysiological abnormalities may precede changes in MRI images (as shown in patients 4 and 5 from this sample) and should, therefore, be accessed in MPS VI patient evaluations, allowing for timely intervention and better prognosis. We recognize the limitations of these data due to the small sample size and recommend further investigation into this patient population. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21813307     DOI: 10.1016/j.ymgme.2011.07.019

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  11 in total

1.  Neonatal gene therapy with a gamma retroviral vector in mucopolysaccharidosis VI cats.

Authors:  Katherine P Ponder; Thomas M O'Malley; Ping Wang; Patricia A O'Donnell; Anne M Traas; Van W Knox; Gustavo A Aguirre; N Matthew Ellinwood; Jason A Metcalf; Bin Wang; Emma J Parkinson-Lawrence; Meg M Sleeper; Doug A Brooks; John J Hopwood; Mark E Haskins
Journal:  Mol Ther       Date:  2012-03-06       Impact factor: 11.454

2.  Isokinetic muscle strength differences in patients with mucopolysaccharidosis I, II, and VI.

Authors:  Natalie E Taylor; Donald R Dengel; Troy C Lund; Kyle D Rudser; Paul J Orchard; Julia Steinberger; Chester B Whitley; Lynda E Polgreen
Journal:  J Pediatr Rehabil Med       Date:  2014

3.  Effect of neonatal gene therapy on lumbar spine disease in mucopolysaccharidosis VII dogs.

Authors:  Lachlan J Smith; John T Martin; Patricia O'Donnell; Ping Wang; Dawn M Elliott; Mark E Haskins; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2012-03-29       Impact factor: 4.797

4.  Spinal cord compression in patients with mucopolysaccharidosis.

Authors:  Tobias Pantel; Mona Lindschau; Andreas M Luebke; Philip Kunkel; Marc Dreimann; Nicole Muschol; Sven O Eicker
Journal:  Eur Spine J       Date:  2022-03-10       Impact factor: 2.721

5.  Evaluation of spinal involvement in children with mucopolysaccharidosis VI: the role of MRI.

Authors:  Elif Bulut; Emine Pektas; Hatice S Sivri; Burcak Bilginer; Mumtaz M Umaroglu; Burce Ozgen
Journal:  Br J Radiol       Date:  2018-02-13       Impact factor: 3.039

Review 6.  Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.

Authors:  Sun H Peck; Margret L Casal; Neil R Malhotra; Can Ficicioglu; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2016-06-04       Impact factor: 4.797

7.  Mucopolysaccharidosis type VI on enzyme replacement therapy since infancy: Six years follow-up of four children.

Authors:  Dafne D G Horovitz; Angelina Xavier Acosta; Liane de Rosso Giuliani; Erlane Marques Ribeiro
Journal:  Mol Genet Metab Rep       Date:  2015-09-30

Review 8.  Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): presentation, diagnosis and management.

Authors:  Guirish A Solanki; Kenneth W Martin; Mary C Theroux; Christina Lampe; Klane K White; Renée Shediac; Christian G Lampe; Michael Beck; William G Mackenzie; Christian J Hendriksz; Paul R Harmatz
Journal:  J Inherit Metab Dis       Date:  2013-02-06       Impact factor: 4.982

Review 9.  Diagnostic and treatment strategies in mucopolysaccharidosis VI.

Authors:  Filippo Vairo; Andressa Federhen; Guilherme Baldo; Mariluce Riegel; Maira Burin; Sandra Leistner-Segal; Roberto Giugliani
Journal:  Appl Clin Genet       Date:  2015-10-30

10.  Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison.

Authors:  Julie B Eisengart; Kyle D Rudser; Yong Xue; Paul Orchard; Weston Miller; Troy Lund; Ans Van der Ploeg; Jean Mercer; Simon Jones; Karl Eugen Mengel; Seyfullah Gökce; Nathalie Guffon; Roberto Giugliani; Carolina F M de Souza; Elsa G Shapiro; Chester B Whitley
Journal:  Genet Med       Date:  2018-03-08       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.